Prime Therapeutics

Hear from our very own Karen Downes on the latest Becker’s Payer Issues Podcast. She discusses the Magellan Rx acquisition, launching new Prime and how Workday technology has supported Prime through it all. Listen to the full podcast episode here: https://apple.co/4hQi1wO

Wishing you a healthy and happy Thanksgiving from all of us at Prime.

Many promising new oncology drugs are making their way through the FDA accelerated approval process. Learn more about recent withdrawn and traditional approvals and those awaiting accelerated approval in the Fall 2024 Prime Therapeutics Report: https://bit.ly/3CyKozo

Our newest High-Cost Therapy Profile has arrived! Dive deeper with our experts here: https://bit.ly/4hWXEy9

The 2024 Medicaid Pharmacy Trend Report is available now! Our expert analysis highlights important conversations and strategic opportunities for managing Medicaid pharmacy programs in the coming years. Topics include traditional and specialty drug spend and impact, the top classes and individual drugs driving trend, and a deeper look the top driver of Medicaid net spend. Check it out: https://bit.ly/3ZdPCcW

🚨 BIG NEWS 🚨 On Dec. 2, 2024, the Magellan Rx website will officially close. But don’t worry — you can visit PrimeTherapeutics.com to find all the benefits info and resources you used to get from Magellan Rx! Check out your new home for all the same solutions, insights and expert support you trust — with a refreshed look and feel. Visit and bookmark PrimeTherapeutics.com today.

Announcing Prime's new quarterly publication, the GLP-1 Pipeline Update! Prime is committed to helping our customers stay ahead of the curve when it comes to GLP-1s. In our GLP-1 Pipeline Update, we track the earliest estimated approvals for GLP-1s new indications. Take a look to learn all about what drugs and changes are coming soon, potentially even as early as December 2024: https://bit.ly/4i14NNJ

Have you read about the latest trends in medical pharmacy? Vaccine utilization across the commercial space rose 169.6% in 2023, led in part by the approval of three new vaccines for respiratory syncytial virus (RSV), as well as full FDA approval for yearly COVID vaccine doses. Across all lines of business, spend on 505(b)(2) agents increased by double digits; however, overall trend for drugs in this space decreased because of lower spend for the innovator products. Read the 2024 Medical Pharmacy Trend Report for more data and expert insights here: https://bit.ly/3OfR8oD

Hear from Simone Ndujiuba, PharmD, BCOP as she discusses the difference between oncology case management and navigation in the latest Oncology Insights. Learn more: https://bit.ly/4hXMs4q

Catch up on the last deep dives of the year! This edition explores therapies for rare diseases like congenital adrenal hyperplasia and familial chylomicronemia syndrome. Highlighted new treatments include: ✔️ Moderate to severe acute pain ✔️ Non-small lung cancer ✔️ Obstructive sleep apnea with obesity Read our latest pipeline to stay ahead of evolving indications and treatments here: https://bit.ly/3OaxtXa